Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pain Therapeutics Inc (NASDAQ:PTIE)

1.86
Delayed Data
As of Aug 28
 +0.11 / +6.29%
Today’s Change
1.53
Today|||52-Week Range
4.50
-8.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$85.1M

Company Description

Pain Therapeutics, Inc. is a biopharmaceutical company, which develops novel drugs. The company is developing a novel drug candidate to treat metastatic melanoma, a deadly form of skin cancer. It has four drug candidates in clinical program, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Contact Information

Pain Therapeutics, Inc.
7801 North Capital of Texas Highway
Austin Texas 78731
P:(512) 501-2444
Investor Relations:

Employees

Shareholders

Mutual fund holders8.07%
Other institutional44.15%
Individual stakeholders32.37%

Top Executives

Remi BarbierChairman, President & Chief Executive Officer
Nadav FriedmannDirector, Chief Operating & Medical Officer
Peter S. RoddyChief Financial Officer & Vice President
Michael J. O'DonnellSecretary & Independent Director
Michael ZamlootSenior Vice President-Technical Operations